ZA200905377B - Polymorphic forms of a macrocyclic inhibitor of HCV - Google Patents

Polymorphic forms of a macrocyclic inhibitor of HCV

Info

Publication number
ZA200905377B
ZA200905377B ZA200905377A ZA200905377A ZA200905377B ZA 200905377 B ZA200905377 B ZA 200905377B ZA 200905377 A ZA200905377 A ZA 200905377A ZA 200905377 A ZA200905377 A ZA 200905377A ZA 200905377 B ZA200905377 B ZA 200905377B
Authority
ZA
South Africa
Prior art keywords
hcv
polymorphic forms
macrocyclic inhibitor
macrocyclic
inhibitor
Prior art date
Application number
ZA200905377A
Other languages
English (en)
Inventor
Sigrid Carl Maria Stokbroekx
Carina Leys
Kelly Ann Swinney
Stijn Wuyts
Andras Horvath
Original Assignee
Tibotec Pharmaceutials Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38229348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200905377(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharmaceutials Ltd filed Critical Tibotec Pharmaceutials Ltd
Publication of ZA200905377B publication Critical patent/ZA200905377B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
ZA200905377A 2007-02-01 2009-07-31 Polymorphic forms of a macrocyclic inhibitor of HCV ZA200905377B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07101563 2007-02-01

Publications (1)

Publication Number Publication Date
ZA200905377B true ZA200905377B (en) 2010-10-27

Family

ID=38229348

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200905377A ZA200905377B (en) 2007-02-01 2009-07-31 Polymorphic forms of a macrocyclic inhibitor of HCV

Country Status (25)

Country Link
US (1) US8143402B2 (xx)
EP (1) EP2118098B1 (xx)
JP (1) JP5523110B2 (xx)
KR (1) KR101580226B1 (xx)
CN (3) CN105037347B (xx)
AR (2) AR065136A1 (xx)
AU (1) AU2008209696B2 (xx)
BR (1) BRPI0806945A2 (xx)
CA (1) CA2677170C (xx)
CL (1) CL2008000321A1 (xx)
CY (1) CY1116339T1 (xx)
DK (1) DK2118098T3 (xx)
ES (1) ES2524784T3 (xx)
HK (2) HK1137438A1 (xx)
HR (1) HRP20141137T1 (xx)
IL (1) IL199215A (xx)
MX (1) MX2009008275A (xx)
NZ (1) NZ577568A (xx)
PL (1) PL2118098T3 (xx)
PT (1) PT2118098E (xx)
RU (1) RU2533830C2 (xx)
SI (1) SI2118098T1 (xx)
TW (1) TWI423968B (xx)
WO (1) WO2008092954A2 (xx)
ZA (1) ZA200905377B (xx)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
CA2753667C (en) * 2009-02-27 2015-11-17 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Amorphous salt of a macrocyclic inhibitor of hcv
WO2010118078A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
BR112012018897A2 (pt) 2010-01-27 2017-10-03 Ab Pharma Ltd Compostos poli-heterocíclicos altamente potentes como inibidores de hcv
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
EP2658859A4 (en) 2010-12-30 2014-07-30 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
BR112013027652A2 (pt) * 2011-05-04 2016-07-26 Merck Sharp & Dohme processo para preparar um composto
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8962810B2 (en) 2011-06-16 2015-02-24 AB Pharma Ltd. Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof
JP2014530177A (ja) * 2011-09-16 2014-11-17 フオベア・フアルマシユテイカル アニリン誘導体、それらの調製およびそれらの治療適用
WO2013059638A1 (en) 2011-10-21 2013-04-25 Abbvie Inc. Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN103826627B (zh) 2011-10-21 2016-02-24 艾伯维公司 包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途
AU2012392557B2 (en) 2012-10-19 2017-06-01 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN105164148A (zh) 2013-03-07 2015-12-16 百时美施贵宝公司 丙型肝炎病毒抑制剂
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN104995189B (zh) * 2014-01-21 2017-03-29 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
CN105308043B (zh) * 2014-05-29 2018-01-30 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
CZ2015220A3 (cs) * 2015-03-27 2016-10-05 Zentiva, K.S. Amorfní sůl makrocyklického inhibitoru viru hepatitidy C
WO2016177625A1 (en) 2015-05-04 2016-11-10 Sandoz Ag Amorphous simeprevir potassium
CN105503851B (zh) * 2015-12-09 2017-06-23 重庆润生科技有限公司 一种烯基噻唑衍生物的制备方法
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004211637C1 (en) * 2003-02-07 2010-08-19 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
JP4525982B2 (ja) * 2003-09-26 2010-08-18 シェーリング コーポレイション Ｃ型肝炎ウイルスのｎｓ３セリンプロテアーゼの大環状インヒビター
CN103145715B (zh) * 2003-10-14 2016-08-03 F·霍夫曼-罗须公司 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺
WO2005073195A2 (en) * 2004-01-30 2005-08-11 Medivir Ab Hcv ns-3 serine protease inhibitors
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c

Also Published As

Publication number Publication date
RU2533830C2 (ru) 2014-11-20
KR20090115929A (ko) 2009-11-10
WO2008092954A2 (en) 2008-08-07
AU2008209696B2 (en) 2013-05-09
BRPI0806945A2 (pt) 2014-05-06
NZ577568A (en) 2012-02-24
ES2524784T3 (es) 2014-12-12
PL2118098T3 (pl) 2015-03-31
CN104230918B (zh) 2018-01-26
US8143402B2 (en) 2012-03-27
EP2118098A2 (en) 2009-11-18
HK1205125A1 (en) 2015-12-11
SI2118098T1 (sl) 2015-01-30
HRP20141137T1 (hr) 2015-01-30
WO2008092954A3 (en) 2008-10-02
CN105037347B (zh) 2018-06-01
US20100029715A1 (en) 2010-02-04
CA2677170C (en) 2017-04-18
EP2118098B1 (en) 2014-09-24
PT2118098E (pt) 2014-12-09
CA2677170A1 (en) 2008-08-07
TW200846347A (en) 2008-12-01
AR065136A1 (es) 2009-05-20
AU2008209696A1 (en) 2008-08-07
RU2009132660A (ru) 2011-03-10
JP2010517971A (ja) 2010-05-27
AR108819A2 (es) 2018-09-26
WO2008092954A8 (en) 2009-12-23
TWI423968B (zh) 2014-01-21
CN104230918A (zh) 2014-12-24
HK1137438A1 (en) 2010-07-30
CN105037347A (zh) 2015-11-11
JP5523110B2 (ja) 2014-06-18
IL199215A (en) 2015-10-29
CL2008000321A1 (es) 2008-08-22
CN101589040A (zh) 2009-11-25
CY1116339T1 (el) 2017-02-08
DK2118098T3 (en) 2014-12-08
KR101580226B1 (ko) 2015-12-24
MX2009008275A (es) 2009-08-12

Similar Documents

Publication Publication Date Title
HK1205125A1 (en) Polymorphic forms of a macrocyclic inhibitor of hcv hcv
HK1245264A1 (zh) 多晶型
HK1217952A1 (zh) 用於製備 的大環蛋白酶抑制劑的方法和中間體
HK1200440A1 (zh) 種抑制劑的結晶形式
HK1156624A1 (en) Crystalline forms of a 2-thiazolyl-4-quinolinyl-oxy derivative, a potent hcv inhibitor hcv 2--4--
HRP20170214T1 (hr) Amorfna sol makrocikličkog inhibitora hcv
PT2094708E (pt) Pirrolopirazina como inibidor da cinase syk
IL196706A0 (en) Crystalline forms of rapamycin analogs
HK1164839A1 (zh) 用於製備 的大環蛋白酶抑制劑的方法及中間體
GB201002676D0 (en) Inhibition of alpha synuclein toxicity
EP2036894A4 (en) AURORA INHIBITOR
GB0619888D0 (en) New polymorphic forms of pregabalin
EP1983997A4 (en) CRYSTALLINE FORMS OF A FARNESYL DIBENZODIAZEPINONE
HK1102210A2 (en) A kind of mending -mouth of pole-charge
ZA200903609B (en) Motilide polymorphs
GB0617364D0 (en) Inflatable show junp